Disease State Burden
Studies to characterize the clinical presentation, progression, and overall burden of chemotherapy-induced myelosuppression in patients with lung cancer, including its impact on patient outcomes and healthcare resource utilization.
This section includes links to Pharmacosmos sponsored-publications and selected Pharmacosmos posters. Information contained in these publications may include information that is inconsistent with the FDA approved use of product(s). Pharmacosmos does not recommend the use of its products in a manner that is inconsistent with FDA-approved labeling. Additionally, the content contained in this section is subject to congress copyright permissions.
*Trilaciclib was developed by G1 Therapeutics which is now subsidiary of Pharmacosmos Therapeutics
May 7 -May 10, 2023 |ISPOR Annual Conference (Poster)
An analysis of patient characteristics associated with myelosuppression among small cell lung cancer patients treated in US community cancer care practices
Gonzalez L, Weerasinghe RK, Sanborn RE, et al.
January-December 2022 | J Med Econ
Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providers
Epstein RS, Weerasinghe RK, Parrish AS, et al.
April 2022 | Cancer Treat Res Commun
Treatment patterns and burden of myelosuppression for patients with small cell lung cancer: A SEER-medicare study
Epstein RS, Nelms J, Moran D, et al.
March 31 –April 2, 2022 | NCCN Annual Conference (Poster)
Burden of myelosuppression among patients with extensive-stage small cell lung cancer treated with chemotherapy in a community oncology setting
Scott J, Slack D, Gingras L, et al.
March 29 –April 1, 2022 | AMCP Annual Meeting (Poster)
Burden of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer: A retrospective study of data from community oncology practices
Hart L, Ogbonnaya A, Boykin K, et al.
February 2021 | Patient Prefer Adherence
Cancer Patients’ Perspectives and Experiences of Chemotherapy-Induced Myelosuppression and Its Impact on Daily Life
Epstein RS, Roy UKB, Aapro M, et al.
August 2020 | Adv Ther
Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid Tumors
Epstein RS, Aapro MS, Roy UKB, et al.